Inhibitors of amyloid beta-protein aggregation mediated by GM1-containing raft-like membranes.

The aggregation (fibril formation) of amyloid beta-protein (Abeta) is considered to be a crucial step in the etiology of Alzheimer's disease (AD). The inhibition of Abeta aggregation and/or decomposition of fibrils formed in aqueous solution by small compounds have been studied extensively for the prevention and treatment of AD. However, recent studies suggest that Abeta aggregation also occurs in lipid rafts mediated by a cluster of monosialoganglioside GM1. This study examined the effects of representative compounds on Abeta aggregation and fibril destabilization in the presence of GM1-containing raft-like liposomes. Among the compounds tested, nordihydroguaiaretic acid (NDGA), rifampicin (RIF), tannic acid (TA), and quercetin (QUE) showed strong fibrillization inhibitory activity. NDGA and RIF inhibited the binding of Abeta to GM1 liposomes by competitively binding to the membranes and/or direct interaction with Abeta in solution, thus at least partly preventing fibrils from forming. Coincubation of Abeta with NDGA, RIF, and QUE in the presence of GM1 liposomes resulted in elongate particles, whereas the presence of TA yielded protofibrillar structures. TA and RIF also destabilized fibrils. The most potent NDGA prevented Abeta-induced toxicity in PC12 cells by inhibiting Abeta accumulation. Furthermore, a comparison of the inhibitory effects of various compounds between aqueous-phase and GM1-mediated aggregation of Abeta suggested that the two aggregation processes are not identical.

[1]  Y. Ihara,et al.  GM1 Ganglioside-Bound Amyloid β-Protein in Alzheimer’s Disease Brain , 1998, Neurobiology of Aging.

[2]  Maarten F. M. Engel,et al.  Islet amyloid polypeptide‐induced membrane leakage involves uptake of lipids by forming amyloid fibers , 2004, FEBS letters.

[3]  A. Takashima,et al.  Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease , 2003, Journal of neurochemistry.

[4]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[5]  L. Tjernberg,et al.  Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand (*) , 1996, The Journal of Biological Chemistry.

[6]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[7]  D. Selkoe,et al.  A Seed for Alzheimer Amyloid in the Brain , 2004, The Journal of Neuroscience.

[8]  T. Bayer,et al.  A modified β‐amyloid hypothesis: intraneuronal accumulation of the β‐amyloid peptide – the first step of a fatal cascade , 2004, Journal of neurochemistry.

[9]  M. Joslyn,et al.  Comparative effects of gallotannic acid and related phenolics on the growth of rats. , 1969, The Journal of nutrition.

[10]  P. Lansbury.  Structural Neurology: Are Seeds at the Root of Neuronal Degeneration? , 1997, Neuron.

[11]  L. Tjernberg,et al.  Controlling Amyloid β-Peptide Fibril Formation with Protease-stable Ligands* , 1997, The Journal of Biological Chemistry.

[12]  L. Choo-Smith,et al.  Acceleration of Amyloid Fibril Formation by Specific Binding of Aβ-(1–40) Peptide to Ganglioside-containing Membrane Vesicles* , 1997, The Journal of Biological Chemistry.

[13]  D. Selkoe,et al.  Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. , 1994, Annual review of cell biology.

[14]  D. Selkoe,et al.  Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. , 1992, Biochemistry.

[15]  K. Ono,et al.  Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. , 2004, Biochimica et biophysica acta.

[16]  K. Blennow,et al.  Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent‐resistant membrane domains , 2005, Journal of neurochemistry.

[17]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .

[18]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[19]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[20]  A. Donald,et al.  The binding of thioflavin-T to amyloid fibrils: localisation and implications. , 2005, Journal of structural biology.

[21]  Y. Kozutsumi,et al.  Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. , 2002, Biochemistry.

[22]  Masaki Wakabayashi,et al.  GM1 Ganglioside-Mediated Accumulation of Amyloid β-Protein on Cell Membranes , 2005 .

[23]  F. Gejyo,et al.  Kinetic analysis of amyloid fibril formation. , 1999, Methods in enzymology.

[24]  S. M. Robinson,et al.  Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease* , 2003, The Journal of Biological Chemistry.

[25]  J. Pettegrew,et al.  Chrysamine G and its derivative reduce amyloid β-induced neurotoxicity in mice , 2002, Neuroscience Letters.

[26]  Claudio Soto,et al.  β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.

[27]  H. Mori,et al.  Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. , 1994, Biochemical and biophysical research communications.

[28]  T. Thomas,et al.  Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation , 2001 .

[29]  Hideyuki Ito,et al.  Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. , 1998, Carcinogenesis.

[30]  Kazuki Sato,et al.  Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Allsop,et al.  Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. , 2002 .

[32]  D. Gordon,et al.  Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Aβ1–40 fibrillogenesis , 2008 .

[33]  P. Fraser,et al.  Structural Transitions Associated with the Interaction of Alzheimer β-Amyloid Peptides with Gangliosides* , 1998, The Journal of Biological Chemistry.

[34]  P. Agostinho,et al.  Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. , 2005, Current drug targets. CNS and neurological disorders.

[35]  S. Hirota,et al.  click peptide based on the O-acyl isopeptide method : Control of Aβ1 42 production from a photo-triggered Aβ1 42 analogue , 2006 .

[36]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[37]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[38]  F. Gejyo,et al.  Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro. , 1998, Biochemistry.

[39]  Y. Ihara,et al.  GM1 ganglioside–bound amyloid β–protein (Aβ): A possible form of preamyloid in Alzheimer's disease , 1995, Nature Medicine.

[40]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[41]  L. Kiessling,et al.  A Strategy for Designing Inhibitors of β-Amyloid Toxicity* , 1996, The Journal of Biological Chemistry.

[42]  J. Harris.  In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition. , 2002, Micron.

[43]  Y. Kozutsumi,et al.  Cholesterol-dependent Formation of GM1 Ganglioside-bound Amyloid β-Protein, an Endogenous Seed for Alzheimer Amyloid* , 2001, The Journal of Biological Chemistry.

[44]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[45]  F. Gejyo,et al.  Interaction between Aβ (1-42) and Aβ (1-40) in Alzheimer's β-amyloid fibril formation in vitro , 1999 .

[46]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[48]  A. Takashima,et al.  Nordihydroguaiaretic acid potently breaks down pre‐formed Alzheimer's β‐amyloid fibrils in vitro , 2002, Journal of neurochemistry.

[49]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[50]  L. Lavoie,et al.  Stereoselective Interactions of Peptide Inhibitors with the β-Amyloid Peptide* , 2003, Journal of Biological Chemistry.

[51]  S. Asano,et al.  Inhibition of Amyloid Protein Aggregation and Neurotoxicity by Rifampicin , 1996, The Journal of Biological Chemistry.

[52]  Katsumi Matsuzaki,et al.  Cross‐seeding of wild‐type and hereditary variant‐type amyloid β‐proteins in the presence of gangliosides , 2005, Journal of neurochemistry.

[53]  Kenjiro Ono,et al.  Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro , 2004, Journal of neuroscience research.

[54]  K. Ono,et al.  Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro , 2005, Neuropharmacology.

[55]  R. Leapman,et al.  Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of β-sheets in Alzheimer's β-amyloid fibrils , 2000 .

[56]  M. Kirkitadze,et al.  Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  L. Svennerholm,et al.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. , 1957, Biochimica et Biophysica Acta.

[58]  Y. Kozutsumi,et al.  Interaction between amyloid β‐protein aggregates and membranes , 2004 .

[59]  W. Richmond.  Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. , 1973, Clinical chemistry.

[60]  D. Selkoe,et al.  Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. , 1998, Biochemistry.